An mRNA assay system demonstrates proteasomal-specific degradation contributes to cardiomyopathic phospholamban null mutation

BACKGROUND: The human L39X phospholamban (PLN) cardiomyopathic mutant has previously been reported as a null mutation but the detailed molecular pathways that lead to the complete lack of detectable protein remain to be clarified. Previous studies have shown the implication between an impaired cellu...

Descripción completa

Detalles Bibliográficos
Autores principales: Rohner, Eduarde, Witman, Nevin, Sohlmer, Jesper, De Genst, Erwin, Louch, William E., Sahara, Makoto, Chien, Kenneth R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425124/
https://www.ncbi.nlm.nih.gov/pubmed/34496741
http://dx.doi.org/10.1186/s10020-021-00362-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425124/
https://www.ncbi.nlm.nih.gov/pubmed/34496741
http://dx.doi.org/10.1186/s10020-021-00362-8

Ejemplares similares